IF 4.9 2区医学

Sleep Pub Date : 2025-09-29 DOI: 10.1093/sleep/zsaf300

Mark S Blumberg

引用次数: 0

Uncovering the overlooked burden: insights from Taiwan on central hypersomnolence. 揭露被忽视的负担：台湾对中枢性嗜睡的见解。

IF 4.9 2区医学

Sleep Pub Date : 2025-09-28 DOI: 10.1093/sleep/zsaf239

Seung-Chul Hong, Suhyung Kim

引用次数: 0

Expanding the Framework on Multimodal Biomarkers in iRBD. Response to Carpi et al. 扩展iRBD中多模态生物标志物的框架。对Carpi等人的回应。

IF 4.9 2区医学

Sleep Pub Date : 2025-09-27 DOI: 10.1093/sleep/zsaf303

Giulia Bruschi, Elisa Bortolin, Maria Vittoria Corbari, Alessandro Bombaci, Salvatore Mazzeo, Massimo Filippi, Maria Salsone

引用次数: 0

Editorial: Social Time Pressure, Sleep, and Eating Rhythms - Lessons from a Pandemic "Natural Experiment". 社评：社会时间压力、睡眠和饮食节奏——流行病“自然实验”的教训。

IF 4.9 2区医学

Sleep Pub Date : 2025-09-27 DOI: 10.1093/sleep/zsaf304

Arman Arab, Frank A J L Scheer

引用次数: 0

From Stages to States: Rethinking Sleep from First Principles. 从阶段到状态：从基本原理重新思考睡眠。

IF 4.9 2区医学

Sleep Pub Date : 2025-09-27 DOI: 10.1093/sleep/zsaf298

Diane C Lim, Cheng-Bang Chen, Ronny P Bartsch

引用次数: 0

Obesity hypoventilation syndrome in the era of GLP-1 receptor agonists and SGLT2 inhibitors: limitations of serum bicarbonate as a screening tool. GLP-1受体激动剂和SGLT2抑制剂时代的肥胖低通气综合征：血清碳酸氢盐作为筛查工具的局限性

IF 4.9 2区医学

Sleep Pub Date : 2025-09-27 DOI: 10.1093/sleep/zsaf297

Ari Manuel, Swapna Mandal, Jean-Louis Pépin, Amanda Piper, Nicholas Hart, Babak Mokhlesi

引用次数: 0

Orexin 1-16 as the stable metabolite behind low CSF orexin/hypocretin immunoreactivity in narcolepsy. 嗜睡症患者脑脊液食欲素/下丘脑分泌素免疫反应性低背后的稳定代谢物是食欲素1-16。

IF 4.9 2区医学

Sleep Pub Date : 2025-09-27 DOI: 10.1093/sleep/zsaf296

Emmanuel Mignot

引用次数: 0

Comparison of Sleep Regularity Index (SRI) scores calculated by open-source packages and implications for outcomes research: rationale and design of the RIRI statement (Reporting Items for Regularity Indices). 由开源软件包计算的睡眠规律指数（SRI）得分的比较及其对结果研究的影响：RIRI声明（规律性指数报告项目）的基本原理和设计。

IF 4.9 2区医学

Sleep Pub Date : 2025-09-26 DOI: 10.1093/sleep/zsaf299

Mark É Czeisler, Josh Leota, Flora Le, Beaudan Campbell-Brown, Shantha M W Rajaratnam, Matthew P Pase, Daniel B Kramer

{"title":"Comparison of Sleep Regularity Index (SRI) scores calculated by open-source packages and implications for outcomes research: rationale and design of the RIRI statement (Reporting Items for Regularity Indices).","authors":"Mark É Czeisler, Josh Leota, Flora Le, Beaudan Campbell-Brown, Shantha M W Rajaratnam, Matthew P Pase, Daniel B Kramer","doi":"10.1093/sleep/zsaf299","DOIUrl":"https://doi.org/10.1093/sleep/zsaf299","url":null,"abstract":"The day-to-day regularity of sleep-wake timing refers to time-varying patterns of behavioral cycles, which co-occur with temporally associated environmental exposures and circadian rhythms. Introduced in 2017, the Sleep Regularity Index (SRI) has enabled rigorous study of the health and performance implications of the day-to-day regularity of sleep-wake timing. Since its introduction, multiple open-source calculators have been published to facilitate SRI scoring from timestamped sleep-wake data; however, the comparability of these calculators had not previously been evaluated. Here, we sought to (1) estimate SRI usage and method of calculation in peer-reviewed studies published since its establishment; (2) compare SRI scores calculated by two widely used SRI calculators, sleepreg and GGIR; (3) compare results from prospective assessments of the relationship between sleepreg SRI scores versus GGIR SRI scores and previously examined health outcomes. We found that amidst increasing use of the SRI, non-disclosure and heterogeneity in the method of SRI calculation are common. Additionally, among more than 70 000 adults with accelerometer-derived sleep-wake data, SRI scores calculated by two widely used open-source packages differed markedly, both in absolute and relative values. Applied to prospective clinical outcome models for all-cause mortality, incident type 2 diabetes, and incident atrial fibrillation or atrial flutter, the method of calculation alone meaningfully changed results and interpretations. In light of these findings, we developed and introduced a 14-item RIRI statement (Reporting Items for Regularity Indices) to standardize reporting and promote reproducibility in research involving the SRI or complementary regularity indices.","PeriodicalId":22018,"journal":{"name":"Sleep","volume":" ","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145150835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of vornorexant in Japanese patients with insomnia: a randomized, placebo-controlled phase 3 pivotal study. vornorexant在日本失眠患者中的疗效和安全性：一项随机、安慰剂对照的3期关键研究。

IF 4.9 2区医学

Sleep Pub Date : 2025-09-26 DOI: 10.1093/sleep/zsaf291

Makoto Uchiyama, Daiji Kambe, Sayaka Hasegawa, Yumiko Imadera, Hironori Yamasaki, Naohisa Uchimura

{"title":"Efficacy and safety of vornorexant in Japanese patients with insomnia: a randomized, placebo-controlled phase 3 pivotal study.","authors":"Makoto Uchiyama, Daiji Kambe, Sayaka Hasegawa, Yumiko Imadera, Hironori Yamasaki, Naohisa Uchimura","doi":"10.1093/sleep/zsaf291","DOIUrl":"https://doi.org/10.1093/sleep/zsaf291","url":null,"abstract":"Study objectives: A placebo-controlled phase 3 study was conducted to evaluate the efficacy and safety of vornorexant, a novel dual orexin receptor antagonist, in Japanese patients with insomnia.Methods: Following a 2-week placebo run-in period, 596 patients with insomnia were randomized to receive 5 mg of vornorexant (VOR5), 10 mg of vornorexant (VOR10), or placebo for 2 weeks in a 1:1:1 ratio in double-blind manner, followed by a 1-week placebo run-out period. The primary and key secondary efficacy endpoints were subjective sleep latency and subjective sleep efficiency, respectively, assessed by sleep diary.Results: Subjective sleep latency was significantly improved at week 2 in both groups compared to placebo (differences of the least-squares mean [LSM] changes from baseline in VOR5, -10.6 min [95% confidence interval - 14.2, -7.0] p<.001, and VOR10, -10.1 min [-13.8, -6.5] p<.001). Subjective sleep efficiency was also significantly improved at 2 weeks in both groups compared to placebo (LSM changes from baseline in VOR5, 3.41% [1.87, 4.96] p<.001, and VOR10, 2.94% [1.40, 4.48] p<.001). The most common adverse event was somnolence (VOR5: 3.1%, VOR10: 3.6%, placebo: 1.5%). No adverse events of cataplexy, fall, muscular weakness, sleep paralysis, hypnagogic or hypnopompic hallucination, or excessive daytime sleepiness were reported. No withdrawal symptoms or rebound insomnia were observed in the placebo run-out period.Conclusion: Treatment with 5 and 10 mg of vornorexant significantly improved sleep onset latency and sleep efficiency compared with placebo without relevant safety concerns.","PeriodicalId":22018,"journal":{"name":"Sleep","volume":" ","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145150930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Quantifying cumulative circadian disruption from shift work and associations with health outcomes in a large cohort of nurses. 在一大群护士中量化轮班工作造成的累积昼夜节律中断及其与健康结果的关系。

IF 4.9 2区医学

Sleep Pub Date : 2025-09-26 DOI: 10.1093/sleep/zsaf301

Linske de Bruijn, Michael Schaapveld, Jelle J Vlaanderen, Roel C H Vermeulen, Hans Kromhout, Flora E van Leeuwen, Nina E Berentzen

{"title":"Quantifying cumulative circadian disruption from shift work and associations with health outcomes in a large cohort of nurses.","authors":"Linske de Bruijn, Michael Schaapveld, Jelle J Vlaanderen, Roel C H Vermeulen, Hans Kromhout, Flora E van Leeuwen, Nina E Berentzen","doi":"10.1093/sleep/zsaf301","DOIUrl":"https://doi.org/10.1093/sleep/zsaf301","url":null,"abstract":"Study objectives: Night shifts are commonly used as proxy for circadian disruption (CD) in epidemiological studies. However, other shift types can also cause CD if they interfere with a worker's biological night. We quantified and compared cumulative CD to night shift exposure and assessed their associations with health-related outcomes.Methods: Shift work exposure was derived from questionnaire data for 42,119 nurses for the period 2012-2017. Cumulative CD was estimated as the total overlap (hours) between shift work and preferred sleep-wake times. Pearson's correlation (r) assessed relationships between cumulative CD and night shift exposure. Associations with sleep disturbances, medication use, and overweight were analyzed using Poisson regression.Results: The median cumulative CD among shift workers was 1,674 hours over six years (interquartile range=432-3,153). High CD (≥2,809 hours) was associated with increased prevalence of sleep problems (incidence rate ratio [IRR]=1.10, 95% confidence interval [CI]=1.07-1.13), melatonin use (IRR=1.86; 95%CI=1.70-2.04), sleep medication use (IRR=1.15; 95%CI=1.01-1.32), and overweight (IRR=1.04; 95%CI=1.02-1.07). The number of performed night shifts strongly correlated with cumulative CD (r=0.93), and using night shifts as proxy for CD gave similar results. However, among shift workers who did not perform night shifts, high CD was still associated with increased sleep problems and melatonin use.Conclusion: Cumulative CD is associated with sleep- and health disturbances, even among shift workers who do not perform night shifts, underlining its potential role in disease development. While night shifts remain a practical proxy in large-scale studies, our study highlights the importance of using more nuanced, individualized measures of CD.","PeriodicalId":22018,"journal":{"name":"Sleep","volume":" ","pages":""},"PeriodicalIF":4.9,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145150902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sleep最新文献